SAB Biotherapeutics, Inc. (NASDAQ:SABSW) Short Interest Up 122.2% in March

SAB Biotherapeutics, Inc. (NASDAQ:SABSW) was the target of a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling 2,000 shares, a growth of 122.2% from the February 28th total of 900 shares. Based on an average daily volume of 29,200 shares, the short-interest ratio is currently 0.1 days.

SAB Biotherapeutics Trading Up 16.7 %

SABSW stock traded up $0.01 during trading on Friday, hitting $0.03. 279 shares of the company traded hands, compared to its average volume of 22,978. The company has a 50-day moving average of $0.04 and a 200-day moving average of $0.05. SAB Biotherapeutics has a 1 year low of $0.01 and a 1 year high of $0.18.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.